Osteoporosis Drug May Slow Joint Destruction In Knee Osteoarthritis
Sunday November 20, 2005
Risedronate brand name Actonel, one of the bisphosphonate drugs typically used in the prevention and treatment of osteoporosis, may slow joint destruction and delay the need for joint replacement surgery in patients with knee osteoarthritis (when taken in higher doses), according to research presented at the ACR Annual Scientific Meeting. Study shows Risedronate (Actonel) May Slow Joint Destruction In Knee Osteoarthritis.
Related Resources:


Comments
No comments yet. Leave a Comment